[EN] SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRIAZOLO-QUINOXALINE SUBSTITUÉS
申请人:GRUENENTHAL GMBH
公开号:WO2020016453A1
公开(公告)日:2020-01-23
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Palladium-catalyzed synthesis of quinoxaline derivatives
作者:Jeffery M. Wallace、Björn C.G. Söderberg、Joaquín Tamariz、Novruz G. Akhmedov、Mathew T. Hurley
DOI:10.1016/j.tet.2008.07.083
日期:2008.10
A palladium-catalyzed reductive N-heteroannulation of enamines derived from 2-nitrobenzenamines forming mixtures of 1,2-dihydroquinoxalines and 3,4-dihydroquinoxalin-2-ones is described. The reactions are performed using bis(dibenzylideneacetone)palladium(0), 1,3-bis(diphenylphosphino)propane, and 1,10-phenanthroline in DMF under 6 atm of carbon monoxide at 70 degrees C. (C) 2008 Elsevier Ltd. All rights reserved.
A Novel Palladium-Catalyzed Synthesis of 1,2-Dihydroquinoxalines and 3,4-Dihydroquinoxalinones
作者:Björn C. G. Söderberg、Jeffery M. Wallace、Joaquín Tamariz
DOI:10.1021/ol025640g
日期:2002.4.1
[GRAPHICS]Reactions of enamines, derived from 2-nitroanilines and alpha-substituted aldehydes, with carbon monoxide (6 atm) in the presence of a catalytic amount of bis(dibenzylideneacetone)palladium(0) (Pd(dba)(2)) and 1,3-bis(diphenylphosphino)propane (dppp) afford readily separated mixtures of 1,2-dihydroquinoxalines and 3,4-dihydroquinoxalinones. Addition of a catalytic amount of 1,10-phenanthroline to the reaction mixture substantially improved the yield of products.
SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES
申请人:Grünenthal GmbH
公开号:EP3823971A1
公开(公告)日:2021-05-26
QUINOXALINE DERIVATIVES
申请人:GRUENENTHAL GMBH
公开号:US20220396578A1
公开(公告)日:2022-12-15
The present invention relates to compounds according to general formula (I)
which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.